SCHEMBL2454641

SCHEMBL2454641

O=C(CCS)ON1C(=O)CCC1=O

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PSMB8 P28062 2/20 0.33
PSMB5 P28074 1/20 0.33
MGLL Q99685 2/20 0.31
LMNA P02545 1/20 0.31
ACE P12821 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13257737 0.89 KMT2A (0.33) PSMB8PSMB5MGLL
SCHEMBL43576 0.87 PSMB8 (0.35) PSMB8PSMB5MGLLLMNA
SCHEMBL18170352 0.85 SMN1; SMN2 (0.38) PSMB8PSMB5
SCHEMBL28630993 0.85 SMN1; SMN2 (0.38) PSMB8PSMB5
SCHEMBL1508845 0.85 SMN1; SMN2 (0.38) PSMB8PSMB5
SCHEMBL31522720 0.85 PSMB8 (0.34) PSMB8PSMB5MGLLLMNA
Mercaptopropionic Acid SCHEMBL1014492 0.84 TSHR (0.35) PSMB8PSMB5ACE
SCHEMBL22777675 0.83 SMN1; SMN2 (0.36) PSMB8PSMB5MGLLLMNA
SCHEMBL2244117 0.83 TSHR (0.36) MGLL
SCHEMBL34383 0.83 SMN1; SMN2 (0.36) PSMB8PSMB5MGLLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250041306-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS INC. (CN) 2025-02-06 US disclosed
CN-118119623-A Targeted protease degradation (TED) platform 嘉兴优博生物技术有限公司 2024-05-31 CN disclosed
CN-115364243-B Construction and application of visual regulation probe for T cell immunocompetence 厦门大学 2024-05-31 CN disclosed
CN-113929738-B Antibody-drug conjugates 第一三共株式会社 2024-05-17 CN disclosed
US-11945848-B2 Chimeric inhibitor molecules of complement activation OMEROS CORPORATION (US) 2024-04-02 US disclosed
US-20240082413-A1 ANTIBODY-DRUG CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-03-14 US disclosed
US-11911999-B2 Plasmonic patch as a universal fluorescence enhancer WASHINGTON UNIVERSITY (US) 2024-02-27 US disclosed
US-20230295252-A1 CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION OMEROS CORPORATION (US) 2023-09-21 US disclosed
US-20230249441-A9 PLASMONIC PATCH AS A UNIVERSAL FLUORESCENCE ENHANCER WASHINGTON UNIVERSITY 2023-08-10 US disclosed
CN-109081871-B Antibody-drug conjugates 第一三共株式会社 2023-07-14 CN disclosed
US-20110130550-A1 PROTEIN MONOMER, PROTEIN POLYMER OBTAINED FROM SAID MONOMER, AND DEVICE THAT CONTAINS THEM OSAKA UNIVERSITY (JP) 2011-06-02 US disclosed
US-7724373-B2 Sub-micron surface plasmon resonance sensor systems INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-05-25 US disclosed
WO-2008100161-A9 SURFACE PLASMON RESONANCE ASSAY FOR STEROIDS THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED (NZ) 2009-09-11 WO disclosed
US-20090081153-A1 COMBINATION OF SYNTHETIC ANTIMICROBIAL POLYMERS AND SESQUITERPENOID COMPOUNDS POLYMEDIX, INC. (US) 2009-03-26 US disclosed
US-20090081153-A1 COMBINATION OF SYNTHETIC ANTIMICROBIAL POLYMERS AND SESQUITERPENOID COMPOUNDS POLYMEDIX, INC. (US) 2009-03-26 US disclosed
WO-2008100161-A1 SURFACE PLASMON RESONANCE ASSAY FOR STEROIDS THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED (NZ) 2008-08-21 WO disclosed
US-20070153284-A1 Sub-Micron Surface Plasmon Resonance Sensor Systems THE TRUSTEES OF INDIANA UNIVERSITY 2007-07-05 US disclosed
US-20060105948-A1 GLP-2 derivatives NOVO NORDISK A/S (DK) 2006-05-18 US disclosed
EP-1608680-A2 GLP-2 DERIVATIVES NOVO NORDISK A/S (DK) 2005-12-28 EP disclosed
WO-2004085471-A2 GLP-2 DERIVATIVES NOVO NORDISK A/S (DK) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250041306-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM ADAMTS1, UCHL3, ADAM33 PSMB8 173/4885PSMB5 264/4885MGLL 1995/4885
US-20060105948-A1 GLP-2 derivatives GLP1R, GIPR, IAPP PSMB8 3580/4885PSMB5 2724/4885MGLL 251/4885
US-20110130550-A1 PROTEIN MONOMER, PROTEIN POLYMER OBTAINED FROM SAID MONOMER, AND DEVICE THAT CONTAINS THEM MAX, MLX, MRPL21 PSMB8 931/4885PSMB5 1151/4885MGLL 1764/4885
US-20090081153-A1 COMBINATION OF SYNTHETIC ANTIMICROBIAL POLYMERS AND SESQUITERPENOID COMPOUNDS LSS, PUF60, FDPS PSMB8 2374/4885PSMB5 1589/4885MGLL 529/4885
US-20240082413-A1 ANTIBODY-DRUG CONJUGATE LANCL2, LANCL1, LCLAT1 PSMB8 1278/4885PSMB5 822/4885MGLL 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.